189 related articles for article (PubMed ID: 35491216)
1. [Allogeneic hematopoietic stem cell transplantations for relapsed and refractory acute lymphoblastic leukemia following inotuzumab ozogamicin treatment].
Morishige S; Yamasaki Y; Oya S; Nakamura T; Yamaguchi M; Aoyama K; Mouri F; Mizushima Y; Nakashima O; Nagafuji K
Rinsho Ketsueki; 2022; 63(4):271-276. PubMed ID: 35491216
[TBL] [Abstract][Full Text] [Related]
2. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
[TBL] [Abstract][Full Text] [Related]
3. Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.
Ladha A; Mannis G; Muffly L
Leuk Lymphoma; 2021 Feb; 62(2):257-263. PubMed ID: 32988266
[TBL] [Abstract][Full Text] [Related]
4. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab.
Agrawal V; Pourhassan H; Tsai NC; Ngo D; Koller P; Malki MMA; Salhotra A; Ali H; Aribi A; Sandhu KS; Arslan S; Ball B; Otoukesh S; Amanam I; Artz A; Singh D; Becker PS; Stewart FM; Smith EP; Curtin P; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pullarkat V; Aldoss I
Transplant Cell Ther; 2023 May; 29(5):314-320. PubMed ID: 36682470
[TBL] [Abstract][Full Text] [Related]
5. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
Fujishima N; Uchida T; Onishi Y; Jung CW; Goh YT; Ando K; Wang MC; Ono C; Matsumizu M; Paccagnella ML; Sleight B; Vandendries E; Fujii Y; Hino M
Int J Hematol; 2019 Dec; 110(6):709-722. PubMed ID: 31655984
[TBL] [Abstract][Full Text] [Related]
6. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
[TBL] [Abstract][Full Text] [Related]
7. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
[TBL] [Abstract][Full Text] [Related]
8. Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).
McDonald GB; Freston JW; Boyer JL; DeLeve LD
Hepatology; 2019 Feb; 69(2):831-844. PubMed ID: 30120894
[TBL] [Abstract][Full Text] [Related]
9. A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.
Izumi A; Tachibana T; Ando T; Tanaka M; Kanamori H; Nakajima H
Int J Hematol; 2022 Jan; 115(1):69-76. PubMed ID: 34490598
[TBL] [Abstract][Full Text] [Related]
10. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186
[TBL] [Abstract][Full Text] [Related]
11. Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and
Kayser S; Sartor C; Luskin MR; Webster J; Giglio F; Panitz N; Brunner AM; Fante M; Lutz C; Wolff D; Ho AD; Levis MJ; Schlenk RF; Papayannidis C
Haematologica; 2022 Sep; 107(9):2064-2071. PubMed ID: 35142153
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Marks DI; Kebriaei P; Stelljes M; Gökbuget N; Kantarjian H; Advani AS; Merchant A; Stock W; Cassaday RD; Wang T; Zhang H; Loberiza F; Vandendries E; DeAngelo DJ
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1720-1729. PubMed ID: 31039409
[TBL] [Abstract][Full Text] [Related]
13. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.
Kayser S; Sartor C; Giglio F; Bruno A; Webster J; Chiusolo P; Saraceni F; Guerzoni S; Pochintesta L; Borlenghi E; Marconi G; Zacheo I; Cerrano M; Salutari P; Restuccia F; Abbenante M; Levis MJ; Schlenk RF; Papayannidis C
Haematologica; 2024 May; 109(5):1385-1392. PubMed ID: 38058184
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
Jabbour EJ; DeAngelo DJ; Stelljes M; Stock W; Liedtke M; Gökbuget N; O'Brien S; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS; Kantarjian HM
Cancer; 2018 Apr; 124(8):1722-1732. PubMed ID: 29381191
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases.
Okura M; Ida N; Yamauchi T
Intern Med; 2020 Aug; 59(16):2047-2051. PubMed ID: 32389945
[TBL] [Abstract][Full Text] [Related]
16. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
Torrent A; Morgades M; García-Calduch O; de Llano MPQ; Montesinos P; Navarro I; Hernández-Rivas JM; Bárez-García A; González-Campos J; Oiartzabal I; Valero M; Cervera M; Zudaire T; Albors-Ferreiro M; López-Godino O; Gil-Cortés C; Villalón L; Saldaña R; Ribera JM
Eur J Haematol; 2023 Sep; 111(3):485-490. PubMed ID: 37381686
[TBL] [Abstract][Full Text] [Related]
17. [Antibody therapy for acute lymphoblastic leukemia].
Hatta Y
Rinsho Ketsueki; 2020; 61(8):922-928. PubMed ID: 32908056
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Chen J; Haughey M; Vandendries E; DeAngelo DJ; Kantarjian HM; Ruiz-Garcia A
Clin Transl Sci; 2021 Jan; 14(1):184-193. PubMed ID: 32812370
[TBL] [Abstract][Full Text] [Related]
19. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD; O'Brien MM
Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
[TBL] [Abstract][Full Text] [Related]
20. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Ho VT; Martin AS; Pérez WS; Steinert P; Zhang MJ; Chirnomas D; Hoang CJ; Loberiza FR; Saber W
Biol Blood Marrow Transplant; 2020 May; 26(5):884-892. PubMed ID: 31891815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]